The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - Grand Rounds in Urology; Ideology Health; Onviv; PeerView; PrecisCa; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Kura Oncology; Loxo/Lilly; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Astellas Pharma; AVEO; Bayer; Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Janssen Oncology; Medscape; Merck; Natera; Pfizer; Research to Practice; Seagen
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Justin A Call
No Relationships to Disclose
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Clinical Care Options
Consulting or Advisory Role - Abbvie (Inst); BostonGene (Inst); BostonGene (Inst); BridgeBio Pharma (Inst); EMD Serono; Fujifilm (Inst); Inspirna (Inst); Jubilant Pharmaceuticals (Inst); Merck (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Sanofi (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Teon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); American Society of Clinical Oncology (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biomea Fusion (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Centessa Pharmaceuticals (Inst); Ciclomed (Inst); Conjupro Biotherapeutics (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); Eikon Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harbour BioMed (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunitas (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kineta (Inst); Kolltan Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); MD Anderson Cancer Center (Inst); MedImmune (Inst); Merck (Inst); Metabomed (Inst); Millennium (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); National Institute of Health (NIH) (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); OncoMed (Inst); Oncorus (Inst); Oncothyreon (Inst); Phanes Therapeutics (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Roche (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tango Therapeutics (Inst); Tarus Therapeutics (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst); Zhuhai Yufan Biotechnologies (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute; Synthorx/Sanofi
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AVEO (Inst); Bayer (Inst); Eisai (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Drew W. Rasco
Research Funding - 23andMe (Inst); Abbvie (Inst); Adcentrx Therapeutics (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Eikon Therapeutics (Inst); Flare Therapeutics (Inst); GlaxoSmithKline (Inst); Johnson & Johnson/Janssen (Inst); Kronos (Inst); Merck (Inst); Molecular Templates (Inst); PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)
 
Lan Liu
Employment - IMPAC Medical Systems
 
Tiantian Niu
Employment - IMPAC Medical Systems
 
Jenna He
Employment - IMPAC Medical Systems
 
Congcong Zhang
Employment - IMPAC Medical Systems
 
Jarema Kochan
Employment - Eikon Therapeutics; Turnstone Bio
Stock and Other Ownership Interests - Eikon Therapeutics
 
Sam Rebello
Employment - Axcella Health; Eikon Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics
 
Giuseppe Russo
Employment - Eikon Therapeutics; Genmab
Stock and Other Ownership Interests - Eikon Therapeutics; Genmab
 
Viola Chen
Employment - Eikon Therapeutics; Mirati Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics
 
Suba Krishnan
Employment - Eikon Therapeutics; Mereo BioPharma
Stock and Other Ownership Interests - Eikon Therapeutics